- Policy
- Ongentys will be reimbursed upon accepting the committee
- by Lee, Hye-Kyung May 12, 2020 06:27am
- SK Chemicals' new drug 'Ongentys (Opicapone)', which is a new treatment for Parkinson's disease, ,accepts below the evaluation amount of the Pharmaceutical Benefits Advisory Committee the reimbursed price will likely pass. The HIRA (President Seon-min Kim) released the results of the deliberation on the adequacy of the medical care benefit
- Policy
- Will generic for Nexavar be released?
- by Lee, Tak-Sun May 11, 2020 06:18am
- The attention is focused whether the generic drug of Nexavar (Sorafenib, Bayer) which has an absolute position as the first drug for liver cancer will be available in the market soon or not. Access to the patient is expected to improve further if the generic for Nexavar which has established an almost exclusive position in the liver cance
- Policy
- Treatment standards are changed in the early stage of MDR-TB
- by Kim, Jung-Ju May 11, 2020 06:17am
- In order to combat multidrug-resistant tuberculosis (MDR-TB), health authorities have changed treatment standards so that new drugs such as Bedaquiline can be used as core drugs even in the early stages of disease. This is to increase the success rate of treatment. The KCDC (Director Eun-Kyeong Jung) has published Korean guidelines for tuberc
- Policy
- Felodipine indication to get limited to stable angina
- by Lee, Tak-Sun May 8, 2020 06:34am
- Felodipine, used on patients with hypertension and angina, is facing an indication adjustment to only treat stable angina when used for angina. Korea Ministry of Food and Drug Safety (MFDS) is planning to finalize the order to change the medicine’s indication on May 22. A calcium channel blocker (CCB), felodipine has a brand-name drug l
- Policy
- People with hepatitis C tx shouldn't take birth control pill
- by Lee, Tak-Sun May 7, 2020 06:01am
- Patients receiving hepatitis C DAA (direct-acting antiviral drugs) will not be able to take the contraceptive containing Ethinylestradiol. This is because the MFDS is pursuing an order to change the permit to add the DAA administration group as a contraindication to patients taking contraceptives based on EMA’s information. Previously,
- Policy
- Truth behind COVID-19 and using antihypertensives
- by Lee, in-bok May 6, 2020 06:33am
- Although a hypertension treatment angiotensin-converting enzyme (ACE) inhibitor has aroused controversy while seeking for COVID-19 treatment, the drug’s safety issues is getting resolved by a series of related clinical investigations. Multiple clinical trials of using ACE inhibitors on COVID-19 patients have confirmed the safety of the drug
- Policy
- Calculation criteria for COVID-19 are being considered
- by Kim, Jung-Ju May 6, 2020 06:32am
- The government said it was in the process of evaluating the calculation standards for medical institutions that participated in Corona 19 response. It means that various types of compensation appear due to treatment segmentation and environment different from that of MERS in the past. Yoon Tae-ho, a senior health ministry official of th
- Policy
- Issues to remain as restricting bioequivalence test scrapped
- by Lee, Tak-Sun Apr 29, 2020 06:19am
- The issues regarding highly saturated first generic market would likely to remain as the Regulatory Reform Committee has axed the Korea Ministry of Food and Drug Safety’s (MFDS) plan to restrict joint and cosigned bioequivalence test. Even if the government grants favorable pricing on generics with individual test data from July, the ind
- Policy
- The MOHW, support for pharmaceuticals entering overseas
- by Lee, Jeong-Hwan Apr 29, 2020 06:19am
- The government will create a &8361;100 billion fund to support domestic biohealth companies that have excellent technology but are having difficulty attracting external investment. The final goal of the fund is to enhance the international competitiveness of Korean bio-health companies and to expand into the global market due to the COVI
- Policy
- Amendment to cascading drug price revision proceeds as it is
- by Kim, Jung-Ju Apr 29, 2020 06:19am
- If the co-biological equivalence test 1 + 3 system is discarded by the Regulatory Reform Committee among the 'Regulation on Pharmaceuticals Approval, Notification and Review', what will happen to the 'cascading drug price revision' of ‘a partial revision of the Criteria for Decision or Adjustment on Drugs’? The MOHW plans to carry out t
